theMednetRegister

Please select the option that best describes you:

Topics: Gastrointestinal Cancers • Medical Oncology • Liver and Pancreas Tumors

When factors would make you choose ipi3/nivo1 frontline for advanced unresectable and metastatic HCC based on Checkmate 9DW?   

As opposed to atezolizumab/bevacizumab or Durvalumab/tremelimumab



Copyright © 2025 theMednet
All Rights Reserved.